Pathophysiological mechanisms of asthma: Application of cell and molecular biology techniques

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 18, Issue 3, 2001, Pages 213-232

  Chung, K F ^a   Adcock, I M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Bronchial hyperresponsiveness; Cytokines; T cells

Indexed keywords

CHEMOKINE; CYTOKINE; EOTAXIN; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 5; MATRIX PROTEIN; PEPTIDOLEUKOTRIENE;

ASTHMA; BRONCHUS HYPERREACTIVITY; CHEMOTAXIS; CYTOKINE RELEASE; EOSINOPHIL; HISTAMINE RELEASE; IMMUNOLOGICAL MEMORY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; RESPIRATORY EPITHELIUM; REVIEW; TH2 CELL;

ANIMALS; ASTHMA; CHRONIC DISEASE; CYTOGENETIC ANALYSIS; CYTOKINES; GENE EXPRESSION; HUMANS; MOLECULAR BIOLOGY; TRANSCRIPTION FACTORS;

BRONCHUS;

EID: 0034928801     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:18:3:213     Document Type: Review

References (186)

1. Guidelines for the management of asthma; a summary
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC
3. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European community Respiratory Health Survey (ECRHS)
4. Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK)
5. Dimished lung fuction asa predisposing factor for wheezing respiratory illness in infants
6. Effect of passive smoking on asthmatic hildren who have and who have not had atopic dermatitis
7. Symptoms of bronchial hyperractivity and asthma in relation to environmental factors
8. Prevalence of wheeze and asthma and relationto atopy in urban and rural Ethiopia
9. Meales and atopy in Guinea-Bissau
10. The inverse association between tuberculin responses and atopic disorder
11. Usual dietary salt intake and asthma in children: A case-control study
12. Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975-81
13. Increased hospitalizations for asthma among children the Washington, D.C. area during 1961-1981
14. Trend in the hospital care of acute childhood asthma 1970-8: A regional study
15. Patients at risk of dying of asthma: New Zealand experience
16. Circumstances of death from asthma
17. A case-control study of deaths from asthma
18. Deaths from asthma in New Zealand
19. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: Case-control study
20. Spectrum of asthma in children. I. Clinical and physiological components
21. Prevalence, natural history, and relationship of wheezy bronchitis and asthma in children. An epidemiological study
22. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort
23. Risk factors for the persistence of respiratory symptoms in childhood asthma
24. Asthma from childhood at age 21: The patient and his disease
25. Rate of decline of lung fuction in subjects with asthma
26. A 15-year follow-up study of ventilatory function in adults with asthma
27. Irreversible airflow obstruction. Evolution in asthma
28. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma; evidence against "intrinsic" asthma being a distinct immunopathologic entity
29. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma
30. Eosinophilic inflammation in asthma
31. Quantitation of most cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry
32. Damage of the airway epithelium and bronchial reactivity in patients with asthma
33. Airway mucosal inflammation even in patients with newly diagnosed asthma
34. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma
35. Immunohistochemical characterization of the cellular infiltration of asthmatic bronchi
36. Bronchoalveolar mast cells in extrinsic asthma: Mechanism for the initiation of antigen specific bronchoconstriction
37. Phenotypic analysis of alveolar macrophages and monocytes in allergic airway inflammation. I. Evidence for activation of alveolar macrophages, but not peripheral blood monocytes, in subjects with allergic rhinitis and asthma
38. Alveolar tissue inflammation in asthma
39. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids
40. Neutrophils may contribute to the pathogenesis of airway inflammation in steroid dependent intractable asthma
41. Airway wall remodelling in asthma
42. Myofibroblasts and subepithelial fibrosis in bronchial 'asthma'
43. Subepithelial fibrosis in the bronchi of asthmatics
44. Bronchial biopsies in asthma: An ultrastructural, quantiative study and correlation with hyperractivity
45. Bronchial biopsy in chronic bronchitis and asthma
46. A Comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema
47. Muscle and mucous gland size in the major bronchi of patients with chronic bronchitis, asthma, and asthmatic bronchitis
48. Hyperplasia of bronchial muscle in asthma
49. Quantitative measurement of bronchial muscle in men with asthma
50. Hyperractive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study
51. Cellular hypertrophy and hyperplasia of airway smooth muscle underlying bronchial asthma
52. Increased vascularity of the bronchial mucosa in mild asthma
53. The mechanics of airway narrowing in asthma
54. Mechanics of airway narrowing
55. Expression and release of interleukin-8 by human airway smooth muscle cells: Inhibition by Th-2 cytokines and corticosteroids
56. Human airway smooth muscle cells express and release RANTES in response to Th-1 cytokines: Regulation by Th-2 cytokines and corticosteroids
57. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: Suppression by dexamethasone
58. Airway smooth muscle cells; contributing to and regulating airway mucosal inflammation?
59. Expression of mRNA for interleukins in mucosal bronchial biopsies from asthma
60. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
61. Membrane-bound and soluble alpha IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics
62. IL-11 expression is increased in severe asthma: Association with epithelial cells and eosinophils
63. IL-9 and its receptor in allergic and non-allergic lung disease: Incresed expression in asthma
64. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma
65. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: Relationship to interleukin-4 and eosinophil counts
66. Cytokines in asthma
67. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF
68. Recombinant human interleukin 5 is a selective activator of human eosinophil function
69. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil factor
70. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells
71. IL-4 directs the development of Th2-like helper effectors
72. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways
73. Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids
74. Endobronchial allergen challenge: Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization
75. Regulatory effect of cytokines on eosinophil degranulation
76. The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils
77. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) pneuloctye-macrophage colony-stimulating factor
78. Expression of RANTES mRNA and protein in airways of patients with mild asthma
79. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells
80. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1a, granulocyte-macrophage colony-stimulating factor and interferon-Y release from alveolar macrophages in asthma
81. Selective enhancement of GM-CSF, TNF-α, IL-1β and IL-8 production by monocytes and macrophages of asthmatic subjects
82. Elevated release of TNF-α and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma
83. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte-macrophage colony stimulating factor by in situ hybridization
84. Increased secretion by tumor necrosis factor α and interleukin 6 by alveolar macrophages consecutive to the development of the late asthmatic reaction
85. Cytokines in symptomatifc asthmatic airways
86. Alveolar macrophage-induced suppression of T-cell hyperresponsiveness in bronchial asthma is reversed by allergen exposure
87. Decreased suppressors cell activity of alveolar macrophages in bronchial athma
88. Expression of interleukin-1 beta(IL-1beta) and interleukin-1 receptor antagonist (IL-Ira) on asthmatic bronchial epithelium
89. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function
90. Heretogeneity of helper/inducer T lymphocytes: Lymphokine production and lymphokine responsiveness
91. Interleukin-4, -5 and -6 and tumor necrosts factor-∞ in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines
92. Interleukin-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: Association with expression of VCAM-1
93. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines effects on neutrophil-epithelial cell adhesion
94. Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukoctye-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways
95. Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients
96. In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: In vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration
97. Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma
98. Expression of endothelial and leukocyte adhesion molecules interacellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma
99. HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis
100. Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep
101. 4-integrin dependent eotaxin-induction of bronchial hyperresponsiveness and eosinophil migration in IL-5 transgenic mice
102. Identification of a lumphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures
103. Eotaxin: A potent eosinophil chemo-attractant cytokine detected in a guinea pig model of allergic airways inflammation
104. Molecular cloning and characterization of a human eotaxin receptor expressed selectivity on eosinophils
105. Co-operation between interleukin-5 and the chemokine, eotaxin, to induce eosinophil accumulation in vivo
106. Human eosinophils have prolonged survival, enhanced functional properties and become hypodense when exposed to human interluekin
107. Expression of mRNA and immunoractivity for the granulocyte/macrophage colony-stimulating factor (GM-CSF) in activated human eosinophils
108. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: Effects on neutrophil-epithelial cell adhesion
109. Alphar4 integrin-dependent eotaxin induction of bronchial hyperresponsiveness and eosinophil migration in interleukin-5 transgenic mice
110. C-fos proto-oncogene expression in bronchial biopsies of asthmatics
111. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma
112. Activation and localization of transcription factor, nuclear factor-kB, in asthma
113. Induction of nitric oxide synthase in asthma
114. Histochemical evidence for induction of arachidonate 15-lipoxygenase in airway disease
115. Increased expression of the monocyte chemoattractant protein-1 in bronchial tissues from asthmatic subjects
116. Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation
117. Differential responsiveness of the IL-5 and IL-4 genes to trasncription factor GATA-3
118. Transcription: Gene control by targeted histone acetylation
119. Inflammatory mediators of asthma: An update
120. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects
121. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects
122. Monocyte chemotactic protein 1 is a potent activator of human basophils
123. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists
124. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy
125. Effects of six weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma
126. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma
127. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
128. Platelet-activating factor in inflammation and pulmonary disorders
129. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma
130. The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma
131. Modulation of cholinergic neutrotransmission in canine airways by thromboxane-mimetic U 46619
132. Prostaglandin D2 potentiates airway responses to histamine and methacholine
133. Induction of bronchial hypersensitivity: Evidence for a role of prostaglandins
134. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects
135. Effect of inhaled prostaglandin E2 on allergen-induced asthma
136. Neuropeptides in the respiratory tract. Part 1
137. NHLBI workshop summaries. Neuroimmune interactions in the lung
138. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge
139. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes
140. Kinins are generated in nasal secretions during natural rhinovirus colds
141. Contractile effects of bradykinin on the isolated human small bronchus
142. Dissociation of bradykinin-induced plasma exudation and reactivity in peripheral airways
143. Effect of kallidin, substance P, and other basic polypeptides on the production of respiratory macromolecules
144. Bradykinin stimulates afferent vagal C-fibers in intrapulmonary airways of dogs
145. Asthma as an axon reflex
146. Is endothelin-1 a mediator in asthma?
147. Immunoractive endothelin in bronchial biopsy specimens: Increased expression in asthma and modulation by corticosteroid therapy
148. Airway endothelin levels in asthma: Influence of endobronchial allergen, challenge and maintenance corticosteroid therapy
149. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid
150. Eosinophil-associated TGFβ1 mRNA expression and airways fibrosis in asthma
151. Increased nitric oxide in exhaled air of asthmatic patients
152. The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways
153. The role of TH1 and TH2 cells in a rodent malaria infection
154. No evidence for effects of family environment on asthma. A retrospective study of Norwegian twins
155. A population-based study of bronchial asthma in adult two pairs
156. Localisation of atopy and beta subunit of high-affinity IgE receptor (Fc epsilon RI) on chromosome 11q
157. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyppresponsiveness
158. Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with amajor gene for atopy
159. Linkage analysis of IL4 and other chromosome 5q31.1. Markers and total serum immunoglobulin E concentrations
160. Investigation of an interleukin-4 promoter polymorphism for associations with asthma and atopy
161. Genetic linkage of T-cell receptor alpha/delta complex to specific IgE responses
162. Association of Glu 27 beta-2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects
163. A genome-wide search for quantitative trait loci underlying asthma
164. Tumor necrosis factor haplotypes asthma
165. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood
166. Early exposure to house-dust mite and cat allergens and development of childhood asthma; a cohort study
167. Primary sensitisation to inhalant allergens in infancy
168. Risk factors in early childhood for the development of atopic diseases
169. Allergic respiratory disease: Strategic targets for primary prevention during childhood
170. The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease
171. CD28/B7 system of T cell costimulation
172. CD80 costimulation is essential for the induction of airway eosinophilia
173. Sudden-onset fatal asthma: A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?
174. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children
175. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo
176. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects
177. Rhinovirus stimulation of interleukin-6 in vivo and in vitro: Evidence for nuclear fator-kB-dependent transcriptional activation
178. Difficult therapy-resistant asthma: Report of a Task Force
179. Corticosteroid responsiveness and the evolution of asthma
180. Steroid resistance in asthma
181. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
182. Accessing genetic information with high-density DNA arrays
183. Expression monitoring by hybridization to high-density oligonucleotide arrays
184. New approaches to the treatment of allergy and asthma
185. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment